Open access · US-GOV
via ClinicalTrials.gov Clinical trial
The Impact of Age and Comorbidity on Effect of Treatment, Adverse Effects and Quality of Life in Danish Lung Cancer Patients Receiving Immunotherapy
Authors not listed
University of Southern Denmark · 2018
Abstract
The LIFE study (Lung cancer, Immunotherapy, Frailty, Effect) is investigating the unselected 'real life' non-small cell lung cancer (NSCLC) population treated with immune checkpoint inhibition.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-31 MST
Cite this
APA
Anonymous. (2018). The Impact of Age and Comorbidity on Effect of Treatment, Adverse Effects and Quality of Life in Danish Lung Cancer Patients Receiving Immunotherapy. <em>University of Southern Denmark</em>. https://clinicaltrials.gov/study/NCT03870464
Vancouver
Anonymous. The Impact of Age and Comorbidity on Effect of Treatment, Adverse Effects and Quality of Life in Danish Lung Cancer Patients Receiving Immunotherapy. University of Southern Denmark. 2018.
BibTeX
@misc{anon2018TheImp,
title = {The Impact of Age and Comorbidity on Effect of Treatment, Adverse Effects and Quality of Life in Danish Lung Cancer Patients Receiving Immunotherapy},
author = {Anonymous},
journal = {University of Southern Denmark},
year = {2018},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Hillel Yaffe Medical Center 2013
Open access · US-GOV
Physical Activity for Improving Quality of Life and Reducing Frailty in Advanced Age: Individually Tailored Program vs the General Guidelines Recommended by Offical Health Organizations.
Instituto Nacional de Cancerologia de Mexico 2016
Open access · US-GOV
Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
UNC Lineberger Comprehensive Cancer Center 2013
Open access · US-GOV
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Intergroupe Francophone de Cancerologie Thoracique 2019
Open access · US-GOV
Phase III Randomized Trial of Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Monthly Carboplatin With Weekly Paclitaxel Chemotherapy
H. Lee Moffitt Cancer Center and Research Institute 2006
Open access · US-GOV
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in the First-Line Treatment of Elderly Patients With Advanced (Stage IIIB(With Malignant Pleural Effusion) or IV) Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Shirish Gadgeel 2021
Open access · US-GOV